Ardelyx

ARDX

Market cap $1.54B

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Thursday, April 30, 2026, at 4:30 p.m.

Michael Raab sold 41,666 shares of common stock for a total of approximately $243,000, with the transaction executed at around $5.84 per share on March 16, 2026. The transaction represented 2.21% of Michael Raab's aggregate and direct holdings at the time, leaving 1,816,448 shares directly owned post-sale.

WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Rajani Dinavahi, MD, as Chief Medical Officer (CMO). Dr. Dinavahi brings more than two decades of experience in healthcare and biotechnology, spanning multiple therapeutic areas and modalities. She has extensive experience across immuno-oncology, autoimmune diseases, metabolic disease, nephrology and transplantation, with a track record of advancing programs from early development through Phase 3 and regulatory approval. Dr. Dinavahi most recently served as Senior Vice President, Chief Medical Officer at Atara Biotherapeutics.

WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, announced the recipients of the 2026 Derek Forfang Patient Advocate Award: Edward Drake II, Markesha Grayson, Timmy Nelson, Pesh Patel and Glenda Roberts.

Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment

WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Leerink Partners 2026 Global Healthcare Conference Location: Miami, FLPresentation: Tuesday, March 10 at 4:20 p.m.

Michael Raab sold 41,666 shares directly on Feb. 24, 2026, for approximately $261,000 at a weighted-average price of $6.25 per share. The sale represented 2.19% of Raab's direct holdings at the time of the transaction.

DAYTONA BEACH, Fla. and WALTHAM, Mass.

Why Ardelyx's Offensive Strategy Doesn't Move The Needle

Ardelyx, Inc. delivered strong FY 2025 revenue growth, driven by Ibsrela, but missed on earnings due to sharply higher SG&A and R&D costs. Ibsrela's accelerating momentum underpins management's guidance for $410–$430M 2026 revenue and a $1B annual target by 2029, supported by patent protection through 2042. Xphozah revenue is declining and maturing, while heavy operational spend and net losses raise concerns about cost discipline and sustainability.